Careers in Science and Bioethics Policy
When: Monday February 13th, 3 to 4 pm
Where: S3.30, King’s College London Strand Campus
About our guests:
Melissa W. Gaule is a recent Bioethics & Society alumna with a background in clinical ethics and patient advocacy, currently working as a consultant for Science Policy Compass.
“After the programme, I felt so excited to start working in my field and immediately started applying for jobs…but I got nothing but rejections! To this day, I have not been called for a single interview. It is so discouraging! Knowing where to start and how to make yourself stand out is such a challenge, especially if you are new to a big city where the job market is so competitive. My answer to this problem was to start building a network of contacts that might be able to help me along the way. In doing this, I ended up finding work with Mark Robertson at his start-up bioethics consulting firm, Science Policy Compass. Finding the time and the confidence to network with the many special people we meet as KCL students can be challenging and uncomfortable, but it is worth it! I will share a bit more about my experience so far and why I think the ability to network is one of our most powerful tools as postgraduates”.
Mark Robertson is Director of Science Policy Compass Ltd. offering science policy / bioethics support and advice important to the bioscience sector. The establishment of a high quality ethical reputation is an essential component to make any science activity attractive in the eyes of investors, collaborators and the general public.
Until August 2016, Mark was Director in the Global Policy & Corporate Responsibility team in Corporate Affairs, AstraZeneca with 7 years dedicated science policy experience. As Chair of the AstraZeneca Bioethics Advisory Group (August 2014 – August 2016), responsible for evolving the AstraZeneca Global Bioethics Policy which included company guidance on the Nagoya Protocol; access to human biological samples for use in research; big data and data privacy; precise genome editing; clinical trials transparency and quality.
Educated at Southampton University, UK and University of Chicago, USA, Mark is a PhD pharmacologist (>50 peer-reviewed publications) and with 30 years Pharma experience mostly in novel medicine project delivery (e.g. 7 years as section manager of Astra pre-clinical team that conceived the principle of and discovered the anti-thrombotic agents, Brilinta and Cangrelor). Worked in several Pharma (including 10 years at GSK), disease areas and business models. Astra/Zeneca corporate merger team member 1999-2000.
In the past 7 years, Mark has specialised on science policy and bioethics. His current interest areas include: Responsible Business and corporate sustainability; corporate reputation, precise genome editing /gene therapy ethics; synthetic biology; chimeras; Nagoya Protocol /biodiversity /access and benefit sharing; clinical trial transparency and quality, donor and patient consent/ data privacy, transparent access to human biological samples for research use
For inquiries about this event please contact: firstname.lastname@example.org